TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2974978
Drug: Incremental doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental doses of calcitonin after 3 injections if blood calcium level had not been reduced by more than 0.4 mmoles/l
Study: 25599346
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with voriconazole and anidulafungin
Study: 30049743
Drug: Voriconazole monotherapy
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole monotherapy
Study: 25599346
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with voriconazole and anidulafungin (post hoc analysis)
Study: 25599346
Drug: Voriconazole monotherapy
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole monotherapy (post hoc analysis)
Study: 22107691
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (vitamin D and phosphate binders)
Study: 12542601
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole (u.i.d) for 14 days
Study: 12542601
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rebamipide (t.i.d) for 14 days
Study: 12542601
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine (b.i.d) for 14 days
Study: 12542601
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg roxatidine (b.i.d) for 14 days
Study: 10632645
Drug: BTC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTC regimen (colloidal bismuth subcitrate 220 mg b.d., tinidazole 500 mg b.d., clarithromycin 250 mg b.d.)
Study: 10632645
Drug: OBTC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBTC regimen (omeprazole 20 mg daily for 4 weeks with BTC regimen during the first week)
Study: 9505989
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg) and Imipramine (75 mg) (combined)
Study: 3090978
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet administered by needle‐catheter jejunostomy (NCJ)
Study: 18657739
Drug: Intra-articular sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular sufentanil (5 microg) with ropivacaine (100 mg) and clonidine (1 microg/kg)
Study: 18657739
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with ropivacaine (100 mg) and clonidine (1 microg/kg) without sufentanil
Study: 16308129
Drug: Regular follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular follow-up by the nutrition team (weekly in hospital, monthly after discharge)
Study: 12549816
Drug: Monthly mail-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly mail-based educational intervention to patients and prescribers regarding medication adherence (intervention group)
Study: 12549816
Drug: Monthly mail-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly mail-based educational intervention
Study: 10367596
Drug: L-DOPA (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (0.10 g, p.o., t.i.d., for 1 day)
Study: 10367596
Drug: L-DOPA (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (0.25 g, p.o., t.i.d., for 2 days)
Study: 10367596
Drug: L-DOPA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (both doses)
Study: 3430499
Drug: Cefonicid (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1-g intravenous dose after cord clamping)
Study: 3430499
Drug: Cefoxitin (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2-g intravenous dose after cord clamping and at 6, 12, and 18 hours postpartum)
Study: 30630805
Drug: Mesalazine +
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine + Bifid Triple Viable Capsules
Study: 26197940
Drug: Short-term oral
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oral immunotherapy (OIT) with Cry j1-galactomannan conjugate
Study: 28509487
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of perindopril and lozartan potassium
Study: 28509487
Drug: Long-term monotherapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term monotherapy with perindopril
Study: 21131668
Drug: 3 to
Normalized name: Melquin-3 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 to 12 mg/d rivastigmine capsules
Study: 21131668
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch groups
Study: 18427220
Drug: Single-point injection
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-point injection of botulinum toxin A into one site
Study: 18427220
Drug: Multiple-points injection
Normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-points injection of botulinum toxin A into two sites on both heads of the gastrocnemius
Study: 18427220
Drug: Single-point injection
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-point injection of botulinum toxin A
Study: 12791614
Drug: Original wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original wheat germ containing 328 mg phytosterols
Study: 30637889
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) treatment regimen (2 mA current, 30 min sessions, twice a week for up to 24 weeks)
Study: 30637889
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) treatment
Study: 21345487
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (10 days of omeprazole plus a single three-in-one capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline)
Study: 21345487
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (7 days of omeprazole, amoxicillin, and clarithromycin)
Study: 19321567
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation (2.5 g with each main meal for 3 months)
Study: 19321567
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation (2.5 g with each main meal for 3 months)
Study: 17348758
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy carried out once weekly for 2 years
Study: 17348758
Drug: Nonmusic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmusic therapy group
Study: 15353506
Drug: Routine abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine abciximab administration
Study: 15353506
Drug: Reperfusion modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion modality (stents or glycoprotein IIb/IIIa inhibitors)
Study: 31504982
Drug: General recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: General recommendations of good oral hygiene including teeth brushing, daily antiseptic mouthwash, and twice a year scaling.
Study: 31504982
Drug: General recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: General recommendations of good oral hygiene.
Study: 28891408
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two matched placebo tablets)
Study: 23170931
Drug: Colesevelam 3.75 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 3.75 g/day plus rosuvastatin 5 mg/day (RC, n=20)
Study: 23170931
Drug: Rosuvastatin 10 mg
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 10 mg (R, n=20)
Study: 21950641
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg (single oral dose)
Study: 21950641
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice/day for 5 days followed by atorvastatin 20 mg (single oral dose) on day 4
Study: 16966616
Drug: Fixed brimonidine-timolol
Normalized name: brimonidine / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed brimonidine-timolol (0.2% brimonidine tartrate and 0.5% timolol maleate) twice daily
Study: 16966616
Drug: 0.2% brimonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% brimonidine tartrate 3 times daily
Study: 1459516
Drug: Octylonium bromide
Normalized name: octylonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octylonium bromide 40 mg tid for 4 weeks
Study: 30289478
Drug: Isavuconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (200 mg IV TID for 2 days, then 200 mg IV OD)
Study: 30289478
Drug: Caspofungin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (70 mg IV OD on day 1, then 50 mg IV OD)
Study: 16723306
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (COCs) with different estrogen/progestogen profiles: EE 20 microg/desogestrel 150 microg, EE 30 microg/desogestrel 150 microg, EE 30 microg/gestodene 75 microg
Study: 3524923
Drug: Steroid and
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid and chlorambucil for six months
Study: 27101669
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) and standardized treatment (glucocorticoid nasal spray)
Study: 27101669
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment (glucocorticoid nasal spray)
Study: 23815304
Drug: Psychoeducational computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational computer-based treatment
Study: 9230790
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (500 mg over five days)
Study: 9230790
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (750 mg over seven days)
Study: 9230790
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment of oral artemether (600 mg) followed by mefloquine (1,250 mg)
Study: 3319349
Drug: Sulindac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (200 mg b.i.d.)
Study: 19835754
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement and provisionalization
Study: 23423595
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without compression treatment
Study: 15504185
Drug: Ketobemidone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketobemidone (1 mg ml(‐1))
Study: 15504185
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg ml(‐1))
Study: 8362431
Drug: Control (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (aspirin therapy)
Study: 8362431
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no aspirin therapy)
Study: 2869952
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg to 60 mg once daily)
Study: 2869952
Drug: Acebutolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (200 mg to 600 mg once daily)
Study: 24657310
Drug: Family-based exposure/response
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based exposure/response prevention therapy (E/RP)
Study: 21104944
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream 0.05% (Finalgon® CPDWärmecreme)
Study: 18182416
Drug: Dihydrocodeine (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine (240 mg)
Study: 12969694
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogen alone or with alendronate
Study: 12969694
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen alone or with alendronate
Study: 12969694
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy plus alendronate
Study: 6221247
Drug: Prednisone 1
Normalized name: prednisone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 1 mg/kg/24 h for one month, then decreasing dosage; cyclophosphamide 2 mg/kg/24 h if failure at one month
Study: 6221247
Drug: Prednisone with
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone with 3 plasma exchanges over a 10-day period, continued weekly if required
Study: 24518158
Drug: T‐cell depleting
Approvals — FDA: no, EMA: no, PMDA: no
Description: T‐cell depleting induction therapy
Study: 12144587
Drug: Alosetron (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron (1-4 mg b.d.)
Study: 7378008
Drug: Other nonprescription
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other nonprescription decongestant preparations
Study: 27816940
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment (mean daily dose: 18.1 mg)
Study: 26606435
Drug: HYC‐24L (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYC‐24L (24 mg/mL of hyaluronic acid, 0.3% lidocaine)
Study: 26606435
Drug: CPM‐22.5 (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPM‐22.5 (22.5 mg/mL of hyaluronic acid)
Study: 24338168
Drug: Low-dose gemcitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gemcitabine (250 mg/m(2)) 6-h infusion on days 1 and 8, and cisplatin (70 mg/m(2)) on day 2 every 21-day cycle (arm 1)
Study: 24338168
Drug: Standard-dose gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose gemcitabine (1,250 mg/m(2)) 30-min infusion on days 1 and 8, with the same dose of cisplatin (arm 2)
Study: 19204651
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) paroxetine
Study: 17458644
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg IV (group O)
Study: 17458644
Drug: lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lornoxicam 8 mg IV (group L)
Study: 17458644
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 2 ml IV (group P)
Study: 15700725
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg plus zolpidem 0 mg
Study: 15700725
Drug: Zolpidem 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 20 mg plus melatonin 0 mg
Study: 15700725
Drug: Melatonin 0
Normalized name: melatonin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0 mg plus zolpidem 0 mg
Study: 21158908
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg alone
Study: 9535248
Drug: PncD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PncD vaccine (1, 3, or 10 microg)
Study: 9535248
Drug: PncD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PncD vaccine
Study: 2645503
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg nandrolone decanoate (ND) intramuscularly every 3 weeks for 1 year
Study: 2645503
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections every 3 weeks for 1 year
Study: 28045314
Drug: CPP‐ACP paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP‐ACP paste (GC Tooth Mousse) applied at each monthly orthodontic follow‐up examination
Study: 28045314
Drug: Routine orthodontic
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine orthodontic treatment (control group)
Study: 18362870
Drug: Bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion XL (150 to 300 mg/day)
Study: 18362870
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 to 20 mg/day)
Study: 12725705
Drug: Rosiglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 2 mg twice daily (R4 + SU)
Study: 12725705
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg twice daily (R8 + SU)
Study: 9043007
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg four times daily
Study: 9043007
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg four times daily
Study: 9043007
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg twice daily
Study: 17404739
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: four doses of 20 ml 40% w/v barium sulphate
Study: 17404739
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: three doses of 20 ml 40% w/v barium sulphate
Study: 17404739
Drug: Regimen C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C: three doses of 20 ml 40% w/v barium sulphate plus 220 ml 2.1% barium sulphate
Study: 17404739
Drug: Regimen D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen D: three doses of 20 ml 40% w/v barium sulphate plus 15 ml diatriazoate megluamine
Study: 17404739
Drug: Reduced-laxative CTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-laxative CTC
Study: 15470825
Drug: L-threodops (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threodops (200 mg orally 2 hours before each session) with physical therapy (PT) and occupational therapy (OT) for 2 months, 3 days a week.
Study: 15470825
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received PT and OT for 4 months without L-threodops.
Study: 29556709
Drug: 11+ injury
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11+ injury prevention program (High Compliance, > 40 doses/season)
Study: 29556709
Drug: 11+ injury
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11+ injury prevention program (Moderate Compliance, 20-39 doses/season)
Study: 29556709
Drug: 11+ injury
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11+ injury prevention program (Low Compliance, 1-19 doses/season)
Study: 26476719
Drug: Morphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (20 mg/10 ml)
Study: 26476719
Drug: Ketamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (50 mg + morphine 10 mg/10 ml)
Study: 26476719
Drug: Saline (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9 % 10 ml)
Study: 24852042
Drug: Guselkumab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (various doses)
Study: 19874691
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + Glutamine 10g tid
Study: 15373927
Drug: Desmopressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (2 microg intravenous dose)
Study: 11772354
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of artemether and praziquantel
Study: 7526096
Drug: Hepatic-artery infusion
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic-artery infusion of floxuridine
Study: 3662274
Drug: Lovastatin 5
Normalized name: niacin/lovastatin 500 mg-20 mg ORAL TABLET,EXTENDED RELEASE MULTIPHASE 24 HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 5 to 40 mg twice daily or 20 to 40 mg once daily in the evening
Study: 31848609
Drug: Whole walnuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole walnuts diet (WD; 57-99 g/d walnuts; 2.7% ALA)
Study: 29122636
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with a history of falling (both treatments)
Study: 28042631
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ordinary treatment only)
Study: 25300690
Drug: L 1,2
Normalized name: glyceryl 1,2-dioleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L 1,2 group (N = 26)
Study: 25300690
Drug: L 2,3
Normalized name: Catechol 2,3-dioxygenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: L 2,3 group (N = 29)
Study: 25300690
Drug: L 3,4
Normalized name: 2-Dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoat
DrugBank: Trimebutine (DB09089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L 3,4 group (N = 27)
Study: 23479319
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg sodium selenite and 30 mg/kg ascorbic acid every 24 h for 4 weeks
Study: 16932894
Drug: Tonsillectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsillectomy plus pulse therapy (prednisolone, warfarin, dipyridamole, methylprednisolone pulse)
Study: 16932894
Drug: PWDM (prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PWDM (prednisolone, warfarin, dipyridamole, mizoribine)
Study: 16932894
Drug: Tonsillectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsillectomy plus pulse therapy